Raptor Pharmaceutical Corp Form 3 January 09, 2015

# FORM 3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF Expires: January 31, 2005

0.5

Estimated average burden hours per

response...

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

(Last)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement  **LAPOINTE ANTHONY** (Month/Day/Year) 01/01/2015 GREGG

(Middle)

(Zip)

Raptor Pharmaceutical Corp [RPTP]

C/O RAPTOR **PHARMACEUTICAL** CORP, Â 7 HAMILTON LANDING, SUITE 100

(Street)

(State)

(First)

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

NOVATO. CAÂ 94949

1. Title of Security (Instr. 4)

(City)

\_X\_ Director 10% Owner Officer Other (give title below) (specify below)

(Check all applicable)

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting Person

6. Individual or Joint/Group

(Instr. 5)

Form filed by More than One

Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form:

> (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership

Direct (D) or Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

Conversion or Exercise Price of

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

#### Edgar Filing: Raptor Pharmaceutical Corp - Form 3

Date Expiration Title Exercisable Date

Amount or Derivative Number of Security Shares Security: Direct (D) or Indirect (I)

(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

LAPOINTE ANTHONY GREGG C/O RAPTOR PHARMACEUTICAL CORP 7 HAMILTON LANDING, SUITE 100 NOVATO, CAÂ 94949

X Â Â Â

### **Signatures**

/s/ Mark Jones, Raptor Pharmaceutical Corp., Attorney-in-Fact

01/09/2015

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Â

#### **Remarks:**

Exhibit 24 Power of Attorney is attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2